Oncology

Latest News

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com

C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

By Jared Kaltwasser

June 7th 2025

The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.

The study identified several molecular markers related to SCLC prognosis by integrating somatic mutation profiles, mRNA transcriptome data, and clinical information. | Image credit: vitstudio - stock.adobe.com

Novel Biomarkers May Inform Prognosis in SCLC

By AJMC Contributor

June 6th 2025

Structured exercise programs should be a part of the standard of care for colon cancer following adjuvant chemotherapy, authors of the COMMANDS study recommended. | Image credit: Drazen - stock.adobe.com

Structured Exercise Program Improves Outcomes, Quality of Life in Colon Cancer

By Rose McNulty

June 6th 2025

young adult cancer | Image credit: Roswell Park Cancer Center

ASCO Sessions Explore Data and Dynamics of Early-Onset Cancer

By Mary Caffrey

June 6th 2025

FDA headquarters | Image Credit: - Tada Images- stock.adobe.com

5 Key FDA Approval Dates Mark a Milestone-Filled May

By Brooke McCormick

June 6th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

November 16th 2018

Keeping Ahead of the Curve in the Transition to Oncology Value-Based Payment

Christina Mattina

At a session of The American Journal of Managed Care®'s Patient-Centered Oncology Care® 2018 meeting, held November 16 in Philadelphia, panelists shared their views on the future of oncology value-based payment models and how they as payers and providers can help advance these models.

November 16th 2018

Dr Marcus Neubauer Discusses the Evolution of Care Teams in Oncology

As practices shift to value-based care, they need truly coordinated care teams that discuss high-risk patients and identify ways to deliver care to them, said Marcus Neubauer, MD, chief medical officer, US Oncology.

November 15th 2018

The New Oncology Bundle Model: What We Know and Don't Know

Darcie Hurteau

CMS' announcement of a new mandatory oncology bundled payment model wasn't a surprise. It reinforces CMS' continued commitment to creating innovative ways of transforming care.

November 14th 2018

Erich Mounce Joins OneOncology as Chief Operating Officer

Former chief exeutive officer of the West Cancer Center brings over 3 decades of technology, operations, and care advancement to the OneOncology National Network.

November 14th 2018

Cancer Surpasses CVD as Leading Cause of Death in High-Income Counties

Jaime Rosenberg

As a result of increased prevention and improved medical treatment of cardiovascular disease (CVD), and despite increasing rates of obesity and diabetes, cancer has gradually surpassed CVD as the leading cause of death in high-income counties. However, CVD is more likely to be the leading cause of death in low-income counties.

November 13th 2018

Cost Burden for Patients With Blood Cancers Eclipses the Burden in Other Cancers

Laura Joszt, MA

Patients with blood cancers are burdened with higher costs than patients with other cancers, and spending in blood cancers does not return to precancer levels, according to a new study from the Leukemia & Lymphoma Society.

November 12th 2018

Nobel Prize Winner Dr James Allison on the Impact His Work Has Made

It has been good knowing that treatments he has had a hand in developing will give years of quality life to patients, where treatments only gave a few months before, explained James Allison, PhD, chair of the Department of Immunology, the Vivian L. Smith Distinguished Chair in Immunology, director of the Parker Institute for Cancer Research, executive director of the Immunotherapy Platform at MD Anderson Cancer Center, and 2018 Nobel Prize cowinner in Medicine.

November 9th 2018

Hospital Cancer Pain Management by Electronic Health Record–Based Automatic Screening

Jinyoung Shin, MD, PhD Hyeonyoung Ko, MD, MPH Jeong Ah Kim, BS Yun-Mi Song, MD, PhD Jin Seok Ahn, MD, PhD Seok Jin Nam, MD, PhD Jungkwon Lee, MD, PhD

A cancer pain control program for inpatients based on electronic health record–based automatic screening provided effective pain relief and achieved high satisfaction among patients and physicians.

November 8th 2018

Azar Announces Mandatory Oncology Payment Model Is Coming

Mary Caffrey Allison Inserro

The announcement is an about-face from earlier efforts that scrapped a cardiac care bundled payment program originally developed during the Obama administration.

November 8th 2018

Dr Thorvardur Halfdanarson on Diagnostics in NETs

Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic, discusses improvements in diagnostics for neuroendocrine tumors, as well as what improvements are still needed.

November 7th 2018

Immunotherapy Improves Survival in Metastatic Melanoma

David Bai, PharmD

The use of CTLA-4, PD-1, or a combination approach achieved high response rates and improved overall survival in patients with CDKN2A mutations with metastatic melanoma, based on the results of a study by Helgadottir et al.

$Early Access to Daratumumab Confirms Safety in Relapsed/Refractory Multiple Myeloma$

November 7th 2018

Early Access to Daratumumab Confirms Safety in Relapsed/Refractory Multiple Myeloma

Laura Joszt, MA

Daratumumab, a human CD38-directed monoclonal antibody, has been confirmed as safe in a population of heavily pretreated patients with multiple myeloma who received access to the treatment before the medication was commercially available, according to an early access treatment protocol study published in Cancer.

November 6th 2018

Hispanics Living With HIV at Increased Risk of HPV-Related Cancers

Jaime Rosenberg

Hispanics living with HIV are at an increased risk of developing cancers caused by the human papillomavirus (HPV) compared to the general Hispanic population, and among people living with HIV, Hispanics are more likely to be diagnosed with cervical and penile cancer.

November 6th 2018

Dr Scott Paulson: Role of Somatostatin Analogs, Biomarkers in Treatment of GEP-NETs

Somatostatins have been the most game-changing drug in the treatment landscape of gastroenteropancreatic neuroendocrine tumors, explained Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center.

November 2nd 2018

Leukemia Survival Improved From 1995 to 2009, but Racial Gaps Increased for Some Types

Laura Joszt, MA

While survival from leukemia improved among adults from 1995 to 2009, and the survival gap between sexes decreased, the racial gap did not, according to new research published in Cancer.

November 1st 2018

New Melanoma Guidelines Identify Recommended Treatments, Weigh In on Genetic Testing

Laura Joszt, MA

New guidelines released by the American Academy of Dermatology will help physicians provide the best treatment for more than 1 million Americans living with melanoma, the deadliest form of skin cancer. The guidelines also highlight the importance of discussions between physicians and patients.

November 1st 2018

Learnings From Priority Health's Oncology Payment Reform Model

Surabhi Dangi-Garimella, PhD

To speak about the success and continued development of Priority Health's payment reform model in cancer care, John Fox, MD, medical director at Priority Health, joined Dennis Zoet, chief business development officer at Cancer and Hematology Centers of Western Michigan, on a panel at the Community Oncology Alliance Payer Exchange Summit.

November 1st 2018

Dr Heloisa Soares on Barriers to Achieving Positive Outcomes in NETs, What's in Store for the Future

Heloisa Soares, MD, assistant professor, University of New Mexico Cancer Center-Albuquerque, outlines current barriers to achieving positive outcomes in neuroendocrine tumors (NETs) and what's in store for the future.

November 1st 2018

Ted Okon on Policy Priorities for COA in 2019

I’ve seen one case recently where a patient received $172,000 of drugs that were totally wasted. So, we’re going to be looking at this, we’re going to be looking at these middlemen getting in the way of the patient and the physician making a decision about their therapy, explained Ted Okon, executive director of COA.

November 1st 2018

Dr Lalan Wilfong Provides an Overview of Key Learnings From the OCM

Looking at total cost of care is difficult and figuring out what the practice is responsible for and not responsible for can be very difficult to do, said Lalan Wilfong, MD, executive vice president of Quality Programs at Texas Oncology.

October 31st 2018

Bo Gamble Explains How COA Defines Value in Oncology

A patient has their own set of values, providers have their own set of values, and the people that pay for it have their own set of values. So, [we all need to] come together, explains Bo Gamble, Director Of Strategic Practice Initiatives at the Community Oncology Alliance.

October 31st 2018

Experts Discuss Regulatory, Cultural Roadblocks to Progress With Value-Based Agreements

Surabhi Dangi-Garimella, PhD

At the Community Oncology Alliance Payer Exchange Summit, healthcare policy experts from a government relations firm and from the pharmaceutical industry provided an update on the progress with value-based agreements and also discussed the challenges posed by the existing infrastructure and operational framework.

October 30th 2018

The Evolution of CLL Testing and Treatment Over the Past Decade

Laura Joszt, MA

In the last decade, testing for and treatment of chronic lymphocytic leukemia (CLL) had undergone substantial changes with new testing that can personalize therapy and new agents that provide more clinical benefit.

October 30th 2018

COA's OCM 2.0: Moving Toward a Universal Payment Model

Surabhi Dangi-Garimella, PhD

The Community Oncology Alliance (COA) has been working with its member practices and some payer partners who have successfully implemented innovative care delivery and payment models to develop a 2.0 version of CMS’ Oncology Care Model (OCM). A progress report was presented at COA’s Payer Exchange Summit held October 29-30 in Tyson’s Corner, Virginia.

October 30th 2018

Community Practices Continue to Struggle With ED Use, Risk Stratification in OCM

Surabhi Dangi-Garimella, PhD

While practice transformation is vital, community-based clinics continue to struggle with emergency department (ED) use, hospitalization, and risk stratification as they identify ways to reduce unnecessary expenditures within their Oncology Care Model (OCM) practice.

October 29th 2018

Implications of OCM Reports and the Future of the Program

Laura Joszt, MA

Lalan Wilfong, MD, moderated a conversation between Robert E. Baird, MD, CEO of Dayton Physicians Network, and Sarah Cevallos, chief revenue cycle officer for Florida Cancer Specialists and Research Institute, about current and future strategies for Oncology Care Model (OCM) participation, as well as key lessons from the OCM and how they can be applied in other reform models.

October 27th 2018

Podcast: This Week in Managed Care—States Gain Power to Alter ACA Offerings and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

October 26th 2018

This Week in Managed Care: October 26, 2018

This week, the top managed care news included the Trump administration giving governors the power to overhaul section 1332 waivers under the Affordable Care Act (ACA); CMS disclosed a breach in the portal that agents and brokers use to assist consumers signing up for health coverage under the ACA; about one-third of all US healthcare payments in 2017 were tied to alternative payment models.

October 26th 2018

Palbociclib Plus Fulvestrant Increases OS in HR+, HER2-Negative Breast Cancer

Samantha DiGrande

A recent trial sought to assess the effect of palbociclib on overall survival (OS) and the efficacy of subsequent therapy in patients with hormone receptor–positive (HR+), HER2-negative advanced breast cancer.

October 25th 2018

Immunotherapy Is Safe for Patients With Cancer Living With HIV

Jaime Rosenberg

According to a study presented at the ESMO 2018 Congress in Munich, Germany, treatment with PD-1 or PD-L1 inhibitors is a feasible option for patients who have cancer and are living with HIV.

...

35 36 37 38 39 40 41 42 43

...

185 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions